NasdaqGS:PRAXBiotechs
A Look At Praxis Precision Medicines (PRAX) Valuation After A Very Large One Year Return
Praxis Precision Medicines snapshot: what recent returns say about the stock
Praxis Precision Medicines (PRAX) has drawn investor attention after a period where the stock is up about 9% over the past month and about 4% over the past 3 months.
Those moves come alongside a reported 1 year total return of about 833% and a market value near US$9.6b, which has put this clinical stage CNS-focused biopharmaceutical company firmly on many growth oriented watchlists.
See our latest analysis for Praxis...